A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Medela Reports Their Portable Medical Surgical and Airway Suction Devices Offers a Safer Alternative to Piped Vaccum Systems

What To Know

  • Standard of care in the ICU requires each patient to be provided with a single suction device, which helps to decrease the risk of lung infections, prolonged hypoxia, and pooling of secretions in the lung.
  • “Medela's range of portable medical surgical and airway suction devices facilitate the removal of lung secretions in the inflammatory process of coronavirus – offering life-saving support to critical care patients while mitigating risks facing staff on the frontlines.

Medela reports their healthcare mobile suction devices are a safer alternative to wall vacuum and can help expand critical care capacity and support UK hospitals in the fight against COVID-19.

Medela notes they have been used in Europe and worldwide. The company’s portable medical suction machines are designed to provide crucial suction and fluid removal during respiratory treatment provided with ventilators.

Traditionally, hospitals ensure a patient’s airway is clear by utilizing suction that relies on central wall piped vacuum. However, guidance published by the National Health Service (NHS) advises hospitals against using piped vacuum to support infectious disease units (IDU) to reduce the risk of virus spread and cross-contamination.

A previous study looking at contamination rates for wall-mounted suction units discovered contamination on over 30% of devices. Hence, portable medical suction machines are recommended for COVID-19 care. Medela offers a range of portable suction pumps which are available with a virus filter capable of reducing cross-contamination from COVID-19 with filtration efficiency of greater than 99.99987%.

These compact devices offer flexibility to hospitals while reducing the risk of viral transmission. When used with disposable collection systems, portable suction machines reduce staff exposure to hazardous fluids, while devices equipped with virus filters further reduce the risk of cross-contamination and viral exposure to staff.

Rob Rennel, Business Unit Manager at Medela comments: “Medela’s range of portable medical surgical and airway suction devices facilitate the removal of lung secretions in the inflammatory process of coronavirus – offering life-saving support to critical care patients while mitigating risks facing staff on the frontlines.”

Dr. Stephen Cole, Consultant in Intensive Care Medicine at Ninewells Hospital in Dundee, Scotland, adds: “The new reality is that we will need to rapidly increase intensive care units (ICU) bed capacity within 2- or 3-weeks’ notice. We need to prepare, need to plan, need to stock the hardware that we need such as ventilators, suction pumps, and monitors.”

While most patients with COVID-19 recover over time without the need for special treatment, in more critical cases the infection can trigger pneumonia, causing the lungs to become more inflamed and fill with fluid. Research shows approximately 14% of COVID-19 patients require hospitalization and oxygen support, while a further 5% require admission to an Intensive Care Unit (ICU) and supportive therapies such as intubation and ventilation.

Standard of care in the ICU requires each patient to be provided with a single suction device, which helps to decrease the risk of lung infections, prolonged hypoxia, and pooling of secretions in the lung.

SourceMedela
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy